Journal article
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities
A Newbold, GM Matthews, M Bots, LA Cluse, CJP Clarke, KM Banks, C Cullinane, JE Bolden, AJ Christiansen, RA Dickins, C Miccolo, S Chiocca, AM Kral, ND Ozerova, TA Miller, JL Methot, VM Richon, JP Secrist, S Minucci, RW Johnstone
Molecular Cancer Therapeutics | AMER ASSOC CANCER RESEARCH | Published : 2013
Abstract
Histone deacetylase inhibitors (HDACi) are anticancer agents that induce hyperacetylation of histones, resulting in chromatin remodeling and transcriptional changes. In addition, nonhistone proteins, such as the chaperone protein Hsp90, are functionally regulated through hyperacetylation mediated by HDACis. Histone acetylation is thought to be primarily regulated by HDACs 1, 2, and 3, whereas the acetylation of Hsp90 has been proposed to be specifically regulated through HDAC6. We compared the molecular and biologic effects induced by an HDACi with broad HDAC specificity (vorinostat) with agents that predominantly inhibited selected class I HDACs (MRLB-223 and romidepsin). MRLB-223, a potent..
View full abstractGrants
Funding Acknowledgements
R.W. Johnstone is a principal research fellow of the National Health and Medical Research Council of Australia (NHMRC) and supported by the NHMRC Program and Project Grants, Cancer Council Victoria, The Leukemia Foundation of Australia, Victorian Breast Cancer Research Consortium, and Victorian Cancer Agency. R.A. Dickins is supported by the NHMRC, Victorian Endowment for Science, Knowledge and Innovation (VESKI) (Australia), and The Sylvia and Charles Viertel Foundation. Work in the laboratory of S. Minucci has been supported by the Association for International Cancer Research (AIRC), Ministry of Health.